Table 1.
Sample characteristics at baseline.
| Variable | Patients (n = 367) |
|---|---|
| Women, n (%) | 281 (76.6%) |
| Age | |
| Mean (SD) | 39.7 (10.8) |
| Range | 18–64 |
| Principal disorder/problem area | |
| Exhaustion disorder, n (%) | 108 (29.4%) |
| Adjustment disorder, n (%) | 66 (18.0%) |
| Depression, n (%) | 59 (16.1%) |
| Generalized anxiety disorder, n (%) | 49 (13.4%) |
| Social anxiety disorder, n (%) | 39 (10.6%) |
| Insomnia, n (%) | 18 (4.9%) |
| Panic disorder, with or without agoraphobia, n (%) | 18 (4.9%) |
| Post-traumatic stress syndrome, n (%) | 5 (1.4%) |
| Obsessive-compulsive disorder, n (%) | 5 (1.4%) |
| Fulfilling full criteria for the principal disorder | 344 (93.7%) |
| Number of patients with comorbid disorder(s) | 202 (55.0%) |
| Education, highest finished, n (%) | |
| Compulsory school, 9 years | 22 (6.0%) |
| Secondary school, 2–3 years | 130 (35.4%) |
| College/university | 215 (58.6%) |
| Psychotropic medication at pre-treatment assessment | |
| Number of patients on any psychotropic medication | 146 (39.8%) |
| Antidepressantsa, n (%) | 59 (16.1%) |
| Anxiety reducing/calminga, n (%) | 43 (11.7%) |
| Sleep medicationa, n (%) | 80 (21.8%) |
| Pain medicationa, n (%) | 11 (3%) |
| Patient recruitment | |
| Clinical trial 1 | 151 (41.1%) |
| Clinical trial 2 | 216 (58.9%) |
a
Patients can be represented in more than one category of psychotropic medication.